Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 2, 2007, Pages 181-186

  Ozer, Erdener ^a   Altungoz, Oguz ^a   Unlu, Mehtat ^a   Aygun, Nevim ^a   Tumer, Sait ^a   Olgun, Nur ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

1p deletion; Angiogenesis; Differentiation; MYCN; Neuroblastoma

Indexed keywords

ADOLESCENT; ANGIOGENESIS; ARTICLE; CHILD; CHROMOSOME 1P; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; INFANT; MALE; MITOSIS; MYCN ONCOGENE; NEUROBLASTOMA; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249714796     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000210418.38246.58     Document Type: Article

References (31)

1. Shimada H, Ambrosi IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364-372.
2. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311:231-235.
3. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. Cancer. 2001;92:2699-2708.
4. Hayashi Y, Kanda N, Inaba T, et al. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 1989;63:126-132.
5. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328:847-854.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
7. Kleinman NR, Lewandowska K, Culp LA. Tumor progression of human neuroblastoma cells tagged with a lacZ marker gene; earliest events at ectopic injection sites. Br J Cancer. 1994;69:670-679.
8. Meitar D, Crawford SE, Rademaker AW, et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 1996;14:405-414.
9. Ribatti D, Alessandri G, Vacca A, et al. Human neuroblastoma cells produce extracellular matrix degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer. 1998;77:449-454.
10. Canete A, Navarro S, Bermudez J, et al. Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol. 2000;18:27-34.
11. Shimada H, Ambrosi IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:348-362.
12. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
13. Fox SB, Leek RD, Weekes MP, et al. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995;177:275-283.
14. Spitz R, Hero B, Skowron M, et al. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Eur J Cancer. 2004;40:2753-2759.
15. Ribatti D, Surico G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 2001;68:1161-1168.
16. 5 are expressed by endothelium of high risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000;60:712-721.
17. Matsunaga T, Takahashi N, Ohnuma N, et al. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. Cancer Res. 1991;51:3148-3152.
18. Negroni A, Scarpa S, Romeo A, et al. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ. 1991;2:511-2518.
19. Ribatti D, Raffaghello L, Pastorino F, et al. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer. 2002;102:351-354.
20. Breit S, Ashman K, Wilting J, et al. The N-myc oncogene in human neuroblastoma cells: downregulation of an angiogenesis inhibitor identified as activin-A. Cancer Res. 2000;60:4596-4601.
21. Hatzi E, Murphy C, Zoephel A, et al. N-myc oncogene overexpression downregulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene. 2002;21:3552-3561.
22. Westermann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Lett. 2002;184:127-147.
23. Bader SA, Fasching C, Brodeur GM, et al. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ. 1991;2:245-255.
24. Ambros IM, Zellner A, Roald B, et al. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med. 1996;334:1505-1511.
25. Chlenski A, Liu S, Cohn SL. The regulation of angiogenesis in neuroblastoma. Cancer Lett. 2003;197:47-52.
26. Huang D, Rutkowski JL, Brodeur GM, et al. Schwann cell-conditioned medium inhibits angiogenesis. Cancer Res. 2000;60:5966-5971.
27. Chlenski A, Liu S, Crawford SE, et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002;62:7357-7363.
28. Ambros PF, Ambros IM, Strehl S, et al. Regression and progression in neuroblastoma: does genetics predict tumor behavior? Eur J Cancer. 1995;31A:510-515.
29. Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. APMIS. 2004;112:413-430.
30. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38:1564-1579.
31. Nagabuchi E, Vanderkolk WE, Une Y, et al. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg. 1997;32:287-293.